Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Human Breast Cancer cells: Control vs Treated with Palbociclib

ABSTRACT: Human Breast Cancer cells: Control vs Treated with Palbociclib

PROVIDER: PRJNA563027 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Gene expression profiles between the palbociclib monotherpy versus palbociclib alternating with ICI182,780 treatment in breast cancer cells at 10 weeks.

Project description:We examined differential gene expression profiles between MCF7 human breast cancer cells treated with vehicle alone (control), palbociclib monotherapy, palbociclib alternating with ICI182,780 treatment, and palbociclib resistant cells. For this, we used gene microarray expression profiling to identify significantly changed genes under different treatment conditions.

2023-04-10 | GSE229002 | GEO

Human Breast Cancer cells: Control vs Treated with Palbociclib

Project description:Analysis miRNA profiling of breast cancer cells treated without or with palbociclib.Results provide insight into the molecular mechanisms involved in resistance to pabbociclib.

2020-04-01 | GSE136671 | GEO

Ethanol treated vs paired control

Project description:Ethanol treated vs paired control

| PRJNA92253 | ENA

Arabidopsis: 3OC8-HSL-treated vs Control

Project description:Arabidopsis: 3OC8-HSL-treated vs Control

| PRJNA810497 | ENA

E-MTAB-2601

Project description:Breast cancer cell lines - palmitate vs control

2025-01-23 | E-MTAB-2601 | ExpressionAtlas

RNA-seq of human breast cancer cell lines MCF7 and T74D naive and resistant to palbociclib treated with capivasertib, fulvestrant and combination

Project description:T47D and MCF7 cell lines were treated with long-term (continuous) palbociclib to induce 4 resistant cell-lines (T47D RB-, T47D CDK6H, MCF7 RB- and MCF7 PacqR). Each cell line (both parental and resistant) were then treated with DMSO (control), capivasertib monotherapy, fulvestrant monotherapy and capivasertib/fulvestrant combination. RNA data is available after each treatment and resistant cell lines additionally have RNA data available after continuous palbociclib treatment.

2023-08-14 | E-MTAB-13262 | biostudies-arrayexpress

RAW macrophages: Control vs. LPS treated or Immunobiotic treated

Project description:RAW macrophages: Control vs. LPS treated or Immunobiotic treated

| PRJNA880829 | ENA

S. coelicolor, control (untreated) vs ciprofloxacin-treated

Project description:S. coelicolor, control (untreated) vs ciprofloxacin-treated

| PRJNA475952 | ENA

Murine testis: control vs. prenatally testosterone treated

Project description:Murine testis: control vs. prenatally testosterone treated

| PRJNA980151 | ENA

Human breast cancer biopsies of patients treated or not with the combination of palbociclib and fulvestrant

Project description:Metastatic HR+ HER2- breast cancer is an intractable disease that resists to the first-line treatment based on the combination of CDK4/6 inhibitor and hormone therapy (HT). To identify targets that further increase palbociclib-HT efficacy, we utilized biopsies from cancer patients who showed recurrence after treatment, HR+HER2- luminal cancer cells sensitive and resistant to the palbociclib-HT. Proteomic analysis of human samples revealed an upregulation of the oxidative stress-triggered proteasome subunit alpha7 (PSMA7) in metastatic relapses in different organs after patient's resistance to palbociclib-HT combination.

2025-05-07 | PXD053296 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data